| abstract |
The present invention demonstrates that the compound N-[2-(7-methoxynaphthalen-1-yl) ethyl] acetamide (agomelatine) inhibits the growth of colon cancer cell lines in vitro as well as in vivo , suggesting the oncostatic/cytotoxic role of this compound. The lines having wild-type p53 demonstrated higher levels of inhibition than those having mutant p53. The effect of the compound depends on the state, mutated or unmutated, of p53, although, unlike melatonin or 5-fluorouracil, the compound is also able to inhibit growth when p53 is mutated, thereby increasing the number of treatable patients. |